MiR-128 modulates chemotherapeutic sensitivity in CSCs by targeting Bmi-1 and Musashi-1, and its reduced expression in cancer tissues is correlated with chemotherapeutic resistance and poor patient outcome15, 16. This evidence concerns the gene BMI1 and cancer.